SIMULTANEOUS ANALYTICAL METHOD DEVELOPMENT OF 6-MERCAPTO¬PURINE AND 6-METHYLMERCAPTOPURINE IN PLASMA BY HIGH PERFOR¬MANCE LIQUID CHROMATOGRAPHY-PHOTODIODE ARRAY by Supandi, Supandi et al.
J Young Pharm, 2017;9(1)Suppl: s29-s34
A multifaceted peer reviewed journal in the field of Pharmacy
www.jyoungpharm.org | www.phcog.net 
Journal of Young Pharmacists, Vol 9, Issue 1(Suppl), Jan-Mar, 2017 S29
Original  Article
Simultaneous Analytical Method Development of 6-Mercapto-
purine and 6-Methylmercaptopurine in Plasma by High Perfor-
mance Liquid Chromatography-Photodiode Array 
Yahdiana Harahap1, Nurul Azizah1, Rizka Andalusia2, Supandi1
1Faculty of Pharmacy Universitas Indonesia, Depok, INDONESIA.
2Department of Research and Development of Dharmais Hospital National Cancer Center, Jakarta, INDONESIA.
ABSTRACT
Objective: 6-Mercaptopurin is antineoplastic drug that is included in antime-
tabolite group and is used in acute lymphoblastic leukemia medication. 6-Mer-
captopurin is inactive pro-drug that will be metabolized into metabolites. One 
of its metabolites is 6-methylmercaptopurine. This study is aimed to optimize 
the analytical conditions and perform validation for the analysis of 6-mercapto-
purine and 6-methylmercaptopurine in plasma. Method: Separation was per-
formed using Waters 2996 HPLC, C18 SunfireTM column (5μm, 250 x 4.6 mm) 
with the mobile phase containing water-methanol-acetonitrile with gradient 
elution, and detected at 303 nm. 5-Fluorouracil was used as internal standard. 
Plasma extraction was done by liquid-liquid extraction using dichloromethane. 
Result: The method was  linear at concentration range of 2.0 – 200.0 ng/mL 
with r > 0.9991 for 6-mercaptopurine and 20 – 2000 ng/mL with r > 0.9993 for 
6-methylmercaptopurine. Accuracy and precision within-run and between-run 
fulfill the acceptance criteria with % RE and relative standard deviation (% 
RSD) ≤ 20% (LLOQ) and ≤ 15% (QC samples). 6-Mercaptopurine and 6-methyl-
mercaptopurine was stable in plasma at least for 21 days when stored at -20ºC. 
Conclusion: The bio-analytical method was sensitive, selective and all the pa-
rameters fulfilled the acceptance criteria of the EMA Bio-analytical Method 
Validation Guideline, 2011.
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INTRODUCTION
6-Mercaptopurine is an antineoplastic drugs which belongs to anti-
metabolites drug and is widely used in childhood acute lymphoblastic 
leukemia medication.1 It is inactive prodrug that will go through three 
metabolic pathways. First, 6-mercaptopurine will be transformed by 
hypoxanthine phosphoribosyl transferase (HPRT) into thioinosine mo-
nophosphate (TIMP) and subsequently into 6-thioxanthosine-5-mono-
phosphate (TXMP) and 6-thioguanosine nucleotides (TGN mono-, di- 
and triphosphate). TGN is active metabolite that will incorporate with 
DNA and induce the breaking of DNA chains. TIMP inhibit ribosyl-
5-phosphate formation, and conversion of inosine-5-monophosphate 
(IMP) into adenine and guanine nucleotides. Second, 6-mercaptopu-
rine will be hydroxylated by xanthine oxidase (XO) into inactive me-
tabolite, 6-thiouric acid. Third, 6-mercaptopurine will be methylated 
by thiopurine methyltransferase (TPMT) into 6-methylmercaptopurine 
(6-MMP). TPMT can also methylate TIMP into methylated thioinosine 
monophosphate (MTIMP). TIMP and MTIMP will inhibit glutamine-
5-phosphoribosyl pyrophosphate amidotransferase, the first enzyme at 
de novo pathway to synthesize purine ribonucleotides.2
6-Mercaptopurine dosing is based on body surface area or patient weight 
so individual therapeutic windows should be noticed. Moreover, there 
are wide inter-individual differences in 6-mercaptopurine metabolism 
among patients receiving identical doses of 6-mercaptopurine.3 Due to 
narrow therapeutic index of 6-mercaptopurine, small amount of dosage 
raise can cause toxicity.4 Based on these reasons, monitoring drug con-
centration in plasma is necessary to assess the safety and efficacy. In the 
present study, the determination of 6-MP and its metabolites in biologi-
cal fluids by reverse phase HPLC have been developed in order to char-
acterize 6-MP pharmacokinetics and pharmacogenetics. Some methods 
of analysis of 6-mercaptopurine and 6-methylmercaptopurine in plasma 
have been performed using high performance liquid chromatography 
with a diode array detector (HPLC-DAD), which produces a detection 
limit of 6-mercaptopurine and 6-methylmercaptopurine of 20 nM.5 
Analysis of 6-mercaptopurine and its metabolites in erythrocytes and 
plasma using HPLC with ultraviolet detector (UV) has been developed 
by Hawwa et al. in 2008. In the study LLOQ 6-mercaptopurine was ob-
tained at 3 pmol / 8 × 108 in erythrocytes and 2 ng / mL in plasma. While 
LLOQ 6-methylmercaptopurine is 3 pmol / 8 × 108 in erythrocytes and 
20 ng / mL in plasma. However, these methods have difficult and com-
plex extraction with derivatization procedure. Most of these methods are 
still using protein precipitation method for the sample preparation that 
causes less purity of extract. Such methods will be adapted to modify the 
method for analysis of 6-mercaptopurine and 6-methylmercaptopurine 
in plasma using HPLC-PDA. This research developed the simple extrac-
tion, quick, and accurate analytical methods of 6-mercaptopurine and 
6-methylmercaptopurine with 5-fluorouracil as internal standard simul-
taneously using HPLC-PDA. The sample preparation used liquid-liquid 
extraction. In this current research, in vitro validation will be performed 
refering to the European Medicine Agency (EMEA) 2011 in term  of 
lower limit of quantification (LLOQ), the linearity of the calibration 
curve, selectivity, carry-over, accuracy, precision, recovery, dilution in-
tegrity, and stability.
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MATERIAL AND METHOD
Chemicals and Reagents
6-Mercaptopurine (6-MP), 6-methylmercaptopurine (6-MMP), 5-fluo-
rouracil (5-FU) were obtained from Sigma Aldrich (St. Louis, MO, 
USA), HPLC grade acetonitrile from Merck, HPLC  grade methanol 
from Merck, ammonium acetate, NH4OH, dichloromethane. All water 
was HPLC grade and prepared using a Millipore Direct-QTM 5Water 
System (Millipore, Watford, UK) and filtrated using Sartorius membrane 
filters [0.45_m] obtained from Sartorius (Epsom, UK). Plasma was ob-
tained from Indonesian Red Cross and stored at -20°C until required.
Instruments
High performance liquid chromatography consists of separation mod-
ule (Alliance 2996; Waters), column heater (Alliance series; Waters), and 
photodiode array detector (Waters 2996). The data were acquired and 
analyzed using Empower TM software.
HPLC Conditions
Separation of 6-MP and 6-MMP was achieved using reverse phase an-
alytical column (C-18 Sun fire™, 5 μm; 250 x 4.6 mm). There are two 
mobile phase. Mobile phase A consists of water-methanol (90:10) and 
mobile phase B consists of water-acetonitrile (75:25). Samples separation 
was performed with gradient elution. The samples were eluted with mo-
bile phase A at the first 6 min and changed to mobile phase B in 7 – 13.50 
min. Elution was continued with mobile phase A to the end of the run at 
16 min. The gradient elution condition profile is shown in Table 1.
Flow rate was maintained at 1 mL/min with column temperature of 
30°C. The photodiode array detector was set at wavelength of 303 nm.
Preparation of Stock Solutions, Calibrators, and Quality 
Control Solutions
The stock solutions of 6-MP and 6-MMP were prepared by dissolving 
appropriate amount of each compound in 0.1 N NH4OH and then dilut-
ing it with water-methanol (50:50). Stock solution of 5-FU was prepared 
by dissolving appropriate amount of 5-FU in water. Stock solutions were 
stored at −20°C until required. Calibrators and quality control solutions 
were prepared by spiking separate stock solutions to human plasma. The 
ranges of the calibration curves were  2 ng/mL, 5 ng/mL, 10 ng/mL, 25 
ng/mL, 50 ng/mL, 100 ng/mL, 150 ng/mL, 200 ng/mL for 6-MP and 20 
ng/mL, 50 ng/mL, 100 ng/mL, 250 ng/mL, 500 ng/mL, 1 µg/mL, 2µg/
mL for 6-MMP. 
Plasma preparation
A 500 μL plasma that contained 6-MP 10 µg/mL and 6-MMP 30 µg/mL 
were mixed with 50 µl 5-FU 30 µg/mL by vortex mixing for 1 min in a 
centrifuge tube. The solutions were added with 5 mL dichloromethane 
and then were vortexed for 2 mins. The tube was then centrifuged for 20 
min at 3000 rpm. The organic phase as much as 3 mL was evaporated 
with N2 for 20 min at 60°C. The residue was then reconstituted with 200 
μL mobile phase (air-methanol-acetonitrile, 90:7:3, v/v, and  30 μL ali-
quot was injected onto the HPLC system.
Method Validation
Lower Limit of Quantification (LLOQ)
LLOQ was validated using five replicates of plasma which were spiked 
with 6-MP and 6-MMP at LLOQ concentration (5% Cmax). % RE and 
% RSD should be ≤ ± 20%. 
Calibration curves
 A blank sample, a zero sample and sample at 8 calibration concentration 
levels were prepared. The slope, intercept and correlation coefficient of 
each calibration curve were determined. % RE should be ≤ ± 15% for 
each calibration concentration and ≤ ± 20% for LLOQ. 
Selectivity
Selectivity is the ability of analytical method to differentiate the com-
pounds of interest with the endogen components in the matrix or other 
compounds in the sample using at least 6 individual sources of matrix. 
The analysis was performed using plasma spiked with the compounds of 
interest at lower concentration (LLOQ). % RE and % RSD should be ≤ 
±20% for LLOQ and 5% for internal standard. 
Carry Over
Carry-over should be minimalized during method development. Carry 
over was performed by injecting blank sample after upper limit of quan-
tification (ULOQ) concentration sample. A carry over ≤ ±20% for LLOQ 
and ≤ ±5% for internal standard are acceptable.
Accuracy, Precision and Recovery
Intra and inter-day accuracy and precision for the developed method 
were determined by analyzing plasma replicates (n= 5) at four different 
concentration (LLOQ, low-, medium-, and high-quality control). Inter-
day analysis was performed on three different days and at five replicates 
of each concentration level whereas intra-day analysis was done on the 
same day. The LLOQ, low-, medium-, and high-quality control concen-
trations of 6-MP were 2 ng/mL, 6 ng/mL, 100 ng/mL and 150 ng/mL, 
while for 6-MMP were 20 ng/mL, 60 ng/mL, 1000 ng/mL and 1500 ng/
mL. 
Accuracy was calculated as the percent error of the measured concentra-
tions with the expected concentrations or expressed as % RE. Precision 
was expressed as % RSD (relative standard deviation). % RE and % RSD 
should be ≤ ± 15% for the QC samples and should be ≤ 20% for LLOQ. 
There are two kinds of recovery; absolute and relative. Absolute recovery 
was determined by comparing peak areas of extracted plasma samples 
with peak areas of aqueous solutions containing the same concentra-
tion of interest compounds which were injected directly into the column 
without extraction. Relative recovery was determined by comparing 
measured concentration with the actual concentration. 
Stability
Evaluation of stability was determined by analyzing plasma samples con-
taining 6-MP and 6-MMP at low-, and high-quality control concentra-
tions.  The stability evaluation consisted of the stock solution and work-
ing solutions of the analyte and internal standard stability, freeze and 
thaw stability, short term stability, long term stability and auto sampler 
stability.
RESULT AND DISCUSSION
Determination of the Lower Limit of Quantification 
(LLOQ)
Based on the research, LLOQ of 6-mercaptopurine was 2 ng/mL and 
had a value of %diff   (-4.62% )- (-3.87%) and % RSD of 3.89%. While 
LLOQ of 6-methylmercaptopurine was 20 ng/mL and % diff was 4.24% 
to 14.11% and % RSD of 3.67%. The value of % diff and % RSD still met 
the requirements so this concentration is elected as LLOQ. The chro-
matogram is shown in Figure 1.
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Calibration Curve
A calibration curve was made  from eight-level concentrations of 6-mer-
captopurine and 6- methylmercaptopurine in the plasma. The concen-
trations of 6-merkaptopurin made  were 2, 5, 10, 25, 50, 100, 150, and 200 
ng/mL. While concentrations of 6-methylmercaptopurine made were 20, 
50, 100, 250, 500, 1000, and 1500 ng/mL. Calibration curve of 6-mercap-
topurine had the correlation coefficient of 0.9991 with the line equation 
y = 0.0004 + 0,0025x. While 6-mercaptopurine had a coefficient correla-
tion of 0.9993 with the line equation y = -0.0014 + 0,0006x. Correlation 
value and % diff obtained from the calibration curve met the require-
ment, that no more than ± 15% for concentration besides LLOQ and no 
more than ± 20% for LLOQ concentration. 
Selectivity
This selectivity test was performed at a concentration of 2 ng/mL for 
6-mercaptopurine and 20 ng/mL for 6-methylmercaptopurine using six 
different human plasma blank to see the effect of plasma impurities from 
different sources. In this research % RE values were obtained between 
9.27%  to 14.93%, relative standard deviation (%RSD) obtained was 
1.89%. Values of % RE and % RSD met the requirements i.e. no more 
than ± 20%, and there was no interference at the retention time of ana-
lyte, metabolite, and internal standard.  Based on the result the method 
can be considered to be selective.
Carry Over
Carry-over of 6-mercaptopurine after injection of ULOQ to the LLOQ 
concentration was 10.49%, 6-methylmercaptopurine was 5.87%, and in-
ternal standard was 0.7%. 
Table 2: Accuracy and Precision of 6-Mercaptopurine Resulted from Method Analysis
Conc.
Day 1 Day 2 Day 3
Measured Conc. 
(ng/mL)
% RSD % RE
Measured 
Conc. (ng/mL)
% RSD % RE
Measured 
Conc. (ng/
mL)
% RSD % RE
2.00 1.93 2.53 -3.71 1.83 2.28 -8.51 2.22 2.37 11.05
1.95 -2.48 1.90 -5.00 2.19 9.41
1.83 -8.66 1.94 -2.78 2.17 8.65
1.93 -3.40 1.91 -4.39 2.20 9.95
1.92 -4.18 1.87 -6.32 2.09 4.34
6.00 5.67 1.69 -5.43 6.02 1.47 0.27 5.97 1.81 -0.49
5.91 -1.51 5.86 -2.40 5.92 -1.25
5.86 -2.33 6.03 0.53 5.73 -4.48
5.72 -4.73 5.88 -2.06 6.01 0.14
5.77 -3.81 5.86 -2.26 5.90 -1.74
100.00 99.92 2.28 -0.08 101.67 2.75 1.67 110.46 4.82 10.46
102.28 2.28 101.19 1.19 109.54 9.54
100.21 0.21 100.17 0.17 101.61 1.61
105.06 5.06 97.43 -2.57 100.88 0.88
104.32 4.32 95.26 -4.74 100.12 0.12
150.00 160.52 0.63 7.01 150.46 0.61 0.30 150.45 0.86 0.30
160.09 6.73 148.68 -0.88 149.35 -0.43
158.26 5.51 150.93 0.62 149.15 -0.57
160.60 7.07 150.87 0.58 149.17 -0.55
159.13 6.09 150.27 0.18 146.94 -2.04
Figure 1: 6-Mercaptopurine and 6-methylmercaptopurine in plasma at LLOQ 
concentration with 5-fluorouracil as internal standard
Table 1: Gradient elution condition profile
Time (minutes) Mobile phase
0 A
1 A
7 B
13.50 B
14 A
15 A
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Accuracy and precision
Accuracy and precision test were performed intra-day and inter-day. 
On the test of intra-day of 6-mercaptopurine, the values of % RE were 
between -5.43% and 7.07% for QCL, QCM, and QCH concentrations. 
While % RE for LLOQ concentrations were -8.66% to -2.48%. In intra-
day accuracy test, % RE of 6-methylmercaptopurine were obtained 
between -1.80% and 7.35% for QCL, QCM, and QCH concentrations 
and between 0.08% to 6.50% for LLOQ concentration. In the inter-day 
accuracy test of 6-mercaptopurine, the % RE were between -5.43% to 
10.46% for QCL, QCM, and QCH concentrations. While % RE for 
LLOQ concentrations were -8.66% to 11.05%. The inter-day accuracy 
test of 6-methylmercaptopurine obtained % RE between -13.19% to 
7.35% for QCL, QCM, and QCH concentrations and % RE between 
-0.96% to 10.08% for LLOQ concentration. The precision could be seen 
from the relative standard deviation (% RSD). The intra-day precision of 
6-mercaptopurine at LLOQ concentration, low, medium, and high con-
centration were respectively 2.53%; 1.69%; 2.28%; and 0.63%. The intra-
day precision of 6-methylmercaptopurine at LLOQ concentration, low, 
medium, and high concentration were respectively 2.57%, 0.88%, 0.83%, 
and 0.12%. The inter-day precision of 6-mercaptopurine at LLOQ, low, 
medium, and high concentration were respectively 7.04%; 1.89%; 3.94%; 
and 3.30%. Inter-day precision of 6-methylmercaptopurine at LLOQ 
concentration, low, medium, and high concentration were respectively 
3.57%, 5.96%, 2.53%, and 2.96% (Table 2 & 3). 
Recovery
The results of relative recovery of 6-mercaptopurin at low, medium, and 
high concentrations were 94.57% - 100.53%; 95.26% - 110.46%; and 
97.96% - 107.07%, respectively. The relative standard deviation (% RSD) 
at low, medium, and high concentration were 1.89%, 3.94%, and 3.30%, 
respectively. While the value of relative recoveries of 6-methylmercapto-
purine at low, medium, and high concentration were 86.81% - 101.44%; 
98.20% - 105.55%; and 98.69% - 107.35%, respectively. The RSD at low, 
medium, and high concentration were 5.96%; 2.53%; and 2.96%, re-
spectively. The absolute recovery of 6-mercaptopurine at low, medium, 
and high concentrations were 92.93% - 109.13%; 95.11% - 102.53%; 
and 95.66% - 102.05%, respectively. The relative standard deviation (% 
RSD) at low, medium, and high concentration were 8.56%, 3.87%, and 
3.23%, respectively. The absolute recovery of 6-methylmercaptopurine 
at low, medium, and high concentrations were 77.16% - 86.02%; 89.46% 
- 91.97%; and 51.39% - 58.23%, respectively. The relative standard devia-
tion (% RSD) at low, medium, high concentration were 5.43%; 1.52%; 
and 6.23%, respectively. It can be concluded that the recovery had good 
extraction efficiency and repeatability. 
Dilution integrity
Intra-day accuracy study of 6-mercaptopurine by the dilution factor of 
1/2 times obtained % RE between -0.56% to 1.02%, while for the dilu-
tion factor of 1/4 times acquired % RE between -10.83% to -6.45%. In 
the inter-day accuracy test 6-merkapatopurin by a factor dilution of 1/2 
times obtained % RE between -5.02% to 1.02% while for the factor dilu-
tion 1/4 times acquired % RE between -10.83% to 0.71%. The intra-day 
precision of 6-mercaptopurine by the dilution factor of 1/2 times and 1/4 
times consecutively obtained % RSD of 0.63% and 1.89%. As for inter-
day precision of 6-mercaptopurine with a dilution factor of 1/2 times 
and 1/4 times consecutively acquired  % RSD 1.72% and 4.32%. The 
Table 3:  Accuracy and Precision of 6-Methylmercaptopurine Resulted from Method Analysis
Conct. (ng/mL)
Day 1 Day 2 Day 3
Measured 
Conct. (ng/mL)
% RSD % RE
Measured 
Conct. (ng/
mL)
% RSD % RE
Measured 
Conct. (ng/
mL)
% RSD % RE
20.00 21.30 2.57 6.50 20.47 1.55 2.36 21.63 0.88 8.15
21.02 5.08 19.81 -0.96 22.02 10.08
20.27 1.35 20.38 1.88 21.76 8.80
20.51 2.55 20.35 1.75 22.01 10.07
20.02 0.08 20.65 3.23 21.64 8.22
60.00 59.45 0.88 -0.92 54.05 1.62 -9.92 60.86 1.31 1.43
60.14 0.24 52.08 -13.19 59.44 -0.93
59.30 -1.16 52.10 -13.16 60.08 0.13
60.22 0.36 53.41 -10.98 60.86 1.44
59.04 -1.60 53.24 -11.26 59.16 -1.40
1000 999.80 0.83 -0.02 1042.67 1.05 4.27 1025.57 1.40 2.56
982.04 -1.80 1055.49 5.55 1007.23 0.72
998.73 -0.13 1054.51 5.45 993.96 -0.60
995.20 -0.48 1040.29 4.03 993.22 -0.68
984.73 -1.53 1028.93 2.89 993.93 -0.61
1500 1608.81 0.12 7.25 1556.30 0.82 3.75 1506.54 0.82 0.44
1607.10 7.14 1556.11 3.74 1510.17 0.68
1610.19 7.35 1529.30 1.95 1508.66 0.58
1609.86 7.32 1553.39 3.56 1503.58 0.24
1605.50 7.03 1561.52 4.10 1480.42 -1.31
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intra-day accuracy  of 6-methylmercaptopurine by the dilution factor of 
1/2 times obtained % RE between -1.31% to 2.15%, while for the dilu-
tion factor of  1/4 times acquired % RE between -4.85% to 0.75%. In the 
inter-day accuracy test of 6-methylmercaptopurine by the dilution factor 
of 1/2 times obtained % RE between -1.31% to 2.15%, while for the 
dilution factor of 1/4 times acquired % RE between -6.8% to 1.24%. The 
intra-day precision of 6-methylmercaptopurine by the dilution factor of 
1/2 times and 1/4 times  obtained % RSD of 1.44% and 2.27%. Inter-day 
precision of 6-methylmercaptopurine by the dilution factor of 1/2 times 
and 1/4 times obtained % RSD of 1.03% and 2.24%.  
Stability Test 
Stock Solutions
Stock solution stability test aimed to see how long stock solution re-
mains stable and can be used, and will affect the efficiency of solution 
preparation time. With stability data obtained, the researchers did not 
need to set up a new stock solution every analysis. Researchers made 
only one stock solution that can be used along the research as long as 
it still meets the limit of stability requirements. The stock solution was 
stable if % RE was not more than ± 2%. The stability test of 6-mercap-
topurine stock solution for one day at room temperature gave the % diff 
of  -0.51% to 0.77%. While the stability test of 6-methylmercaptopurine 
stock solution for one day at room temperature gave % RE of -1.76% 
to 1.18%. Long-term storage at 4°C of 6-mercaptopurine and 6-methyl-
mercaptopurine stock solution remained stable at least for 21 days with 
% RE of -1.99% up to -0.66% for 6-mercaptopurine and  -1.97% to 
-1.27% for 6-methylmercaptopurine.
Freeze-Thaw Stability 
The freeze-thaw stability test was performed using solutions at QCL and 
QCH concentrations and then stored for three cycles of freeze and thaw. 
The solutions were stable if % RE values were not more than ± 15%. 
From the research, % RE at low and high concentration of 6-mercap-
topurine were -14.52% to -0.19% and -13.05% to 1.22%, respectively. 
While the % RE of 6-methylmercaptopurine at low and high concentra-
tion were -12.55% to 0.97% and -7.08% to 1.93%, respectively. There-
fore, the solutions were stable after three cycles of freeze and thaw. 
Short-term Stability
Short-term stability is done by store the QCL and QCH solutions for 24 
hours and performed the injection to be analyzed on the hour 0, hour-6, 
and the 24th hour. Solution declared stable after storage for 24 hours at 
room temperature, if the value of % RE not more than ± 15%. From the 
research value of % RE QCL and QCH concentrations of 6-mercaptopu-
rine were -12.44% to -2.81% and -2.75% to 3.03%, respectively, while 
for 6-mercaptopurine were  -10.22% to 2.72% and -2.05% to 6.40%, 
respectively. Thus, it can be stated that the solution stable at room tem-
perature for 24 hours.
Long-term Stability
Long-term stability was performed at low and high concentrations. The 
samples were stored on days 0, 7, 14, and 21. The solution was stated 
stable for storage after preparation in the plasma if % RE stability is not 
over ± 15%. Based on the result, QCL and QCH of 6-mercaptopurine 
and 6-methylmercaptopurine were still stable until day 21st with % RE 
value for 6-mercaptopurine were -14.79% to 4.38% and -5.68% to 4.50%, 
respectively, while for 6-methylmercaptopurine were -10.96% to 1.59% 
and 3.56% to 7.46%, respectively. 
Auto sampler Stability
Auto sampler stability test conducted on hour-0 and 24 after the solution 
was extracted and stored in the auto sampler. This test was performed 
at QCL and QCH concentrations. The solution was declared stable af-
ter storage for 24 hours in auto sampler if the % RE is not more than 
± 15%. Based on the results, QCL and QCH of 6-mercaptopurine and 
6-methylmercaptopurine were stable during storage in the auto sampler 
for 24 hours, with %RE for 6-mercaptopurine were 12.11% to 12.64% 
and -0.21% to 1.19%, while for 6-methylmercaptopurine were 13.01% 
to 14.03% and 3.99% to 4.98%. Thus, it can be stated that solutions were 
stable during storage in the auto sampler for 24 hours. 
DISCUSSION
This research developed analytical methods of 6-mercaptopurine and 
6-methylmercaptopurine in plasma with 5-fluorouracil as the internal 
standard simultaneously using photodiode array detector (PDA). The 
sample preparation used liquid-liquid extraction with dichloromethane 
as the solvent and the separation was conducted using gradient elution 
on C
18
 column.  The extraction process used 500 µL plasma contain 
6-mercaptopurine, 6-methylmercaptopurine and 5-fluorouracil then ex-
tracted with 5 mL dichlormethane (1:10 v/v).
The method had been validated refers to the European Medicine Agency 
(EMA) 2011 in term of lower limit of quantification (LLOQ), the linear-
ity of the calibration curve, selectivity, carry-over, accuracy and preci-
sion, recovery, dilution integrity, and stability. LLOQ value associated 
with the sensitivity of a method for measuring the levels of analytes in 
biological matrices. The smaller the LLOQ, then these methods will be 
more sensitive to measure the low levels of analytes in biological ma-
trices, moreover there was the metabolites in the sample. LLOQ value 
is one per twenty maximum concentration of the analyte in the plasma 
(Cmax).
All validation parameters fulfill the EMA 2011 criteria with LLOQ of 
6-mercaptopurine was 2 ng / mL, while the LLOQ of 6-methylmercap-
topurine was 20 ng/mL which lower than 5% of Cmax. The method  of 
6-mercaptopurine was linear in range concentration of  2 ng/mL - 200 
ng/mL, while 6-methylmercaptopurine was linear in the range of 20 ng/
mL - 1500 ng/mL. Typical HPLC chromatograms of blank plasma and 
blank plasma spiked with 6-mercaptopurine and 6-methylmercaptopu-
rine LLOQ and IS were shown in Figure 1. Retention times of 6-mercap-
topurine and 6-methylmercaptopurine and IS were 1.04 and 0.95 min, 
respectively. No significant interfering peak was observed around the 
6-mercaptopurine and 6-methylmercaptopurine and IS.
Based on the data, the method was accurate and precise and was stable 
for 3 freeze-thaw cycles, 24 hours in room temperature, 24 hours on auto 
sampler, and 21 days at -20°C. Furthermore, LLE provided clean extracts 
and the recovery had good extraction efficiency and repeatability with 
no interferences presented on the chromatograms.
The method can be applied for supporting the therapeutic drug monitor-
ing on Childhood Leukemia Lymphocytic Acute patients.
CONCLUSION
The analytical method was valid and linear at concentration range of 2.0 
– 200.0 ng/mL for 6-mercaptopurine and 20 – 2000 ng/mL for 6-meth-
ylmercaptopurine. All the parameters fulfilled the acceptance criteria of 
the EMA Bioanalytical Method Validation Guideline, 2011. 
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ABBREVIATIONS USED
HPLC-PDA: High Performance Liquid Chromatography-Photodiode 
Array; 6-MP: 6-Mercaptopurine; 6-MMP: 6-Methylmercaptopurine; 
HPRT: Hypoxanthine Phosphoribosyl transferase; TIMP: Thioinosine 
monophosphate; TXMP: Thioxanthosine Monophosphate; TGN: Thio-
guanosine Nucleotides; DNA: Deoxyribonucleic Acid; IMP: Inosine 
Monophosphate; XO: Xanthine Oxidase; TPMT: Thiopurine Methyl-
transferase; MTIMP: Methylated Thioinosine Monophosphate; EMEA: 
European Medicine Agency; LLOQ: Lower Limit of Quantification; 
ULOQ: Upper Limit of Quantification; 5-FU: 5-fluorouracil; RE: Rela-
tive Error; RSD: Relative Standar Deviation; QC: Quality Control; QCL: 
Quality Control Low; QCM: Quality Control Medium; QCH: Quality 
Control High.
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